# Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/obc

## Mild One-Pot Horner-Wadsworth-Emmons Olefination and Intramolecular *N*-arylation for the Syntheses of Indoles, All Regio-isomeric Azaindoles, and Thienopyrroles

Ji Hye Choi<sup>1, 2</sup>, Hwan Jung Lim \*<sup>1, 3</sup>

Address: <sup>1</sup>Medicinal Chemistry Research Center, Korea Research Institute of Chemical Technology, Daejeon 305-345, Republic of Korea and <sup>2</sup>Department of Chemistry, Hanyang University, Seoul, 133-791, Republic of Korea and <sup>3</sup>Department of Medicinal and Pharmaceutical Chemistry, University of Science & Technology, 217 Gajeong-ro, Daejeon 305-350, Republic of Korea

Email: indium@krict.re.kr

\* Corresponding author

### Abstract

The syntheses of various *N*-protected aromatic-ring fused pyrrole-2-carboxylate derivatives have been accomplished using mild one-pot Horner-Wadsworth-Emmons olefination and Cucatalyzed intramolecular *N*-arylation reactions. The optimized mild one-pot reaction conditions of various 2-bromo arylcarboxaldehyde with commercially available *N*-protected phosphonoglycine trimethylesters gave the desired aromatic-ring fused pyrrole-2-carboxylates, such as substituted indole-, all regio-isomeric azaindole-, and thienopyrrole-2-carboxylates, in good to excellent yields. These conditions showed broad substrate compatibility, without the loss of the protecting group.

## Keywords

One-pot; Indole; Azaindole; Thienopyrrole; Copper; *N*-arylation; Horner-Wadsworth-Emmons

## Introduction

Pyrrole is a prototypical 5-membered heterocycle, and methods for pyrrole syntheses and its' reactivity patterns are well established.<sup>[1,2]</sup> Representative pyrrole-ring syntheses are the Paal-Knorr synthesis,<sup>[2a]</sup> Hantzsch synthesis,<sup>[2b]</sup> and Kenner synthesis,<sup>[2c]</sup> as well as recent examples that utilize metal-catalyzed coupling reactions.<sup>[2d]</sup> Pyrrole fused-heterocycles such as indoles and azaindoles are also crucial targets requiring the development of efficient synthetic methods for various purposes.<sup>[1,3]</sup> Among these compounds, fused pyrrole-2-carboxylates are one of the most versatile precursors for the construction of more complex natural products and medicinally important molecules. The synthesis of porphobilinogen from 6-azaindole,<sup>[4a]</sup> the potent anti-cancer agent CC-1065 from pyrrolo-indole,<sup>[4b]</sup> duocarmycin A from indole,<sup>[4c]</sup> and other novel compounds with high potency are a few representative examples (Figure 1).<sup>[5]</sup> Moreover, in recent efforts to develop new materials for varying applications, such as semiconductors, glucose sensors, and fluorescence-emitting dyes, pyrrole has become an indispensable structural unit.<sup>[6]</sup>



Figure 1: Pyrrole-2-carboxylate Containing Natural Products and Drugs.

For the synthesis of pyrrole-fused heterocycles, recent efforts have focused on developing methods for the preparation of diverse substituted pyrrole-fused heterocycles under mild conditions using straightforward procedures without any special equipment. Among them, a strategy based on the metal-catalyzed intramolecular *N*-arylation<sup>[7]</sup> of 1-alkyl substituted 2-haloarenes, initially reported by Buchwald and his coworkers,<sup>[8a]</sup> is one of the most promising tactics to achieve these goals.<sup>[4c,8]</sup> There are many studies related to the metal-catalyzed intramolecular N-arylation for the syntheses of various heterocycles, and some results for the formation of indoles are summarized in Figure 2.

**Organic & Biomolecular Chemistry Accepted Manuscript** 



Figure 2: Reported Synthetic Approaches via a Metal-Catalyzed Intramolecular N-Arylation.

The reported methods clearly show the utility of this concept for the preparation of various indole derivatives, and they primarily involve stepwise formation of C-C or C-N bonds and then *N*-arylation sequences. In a few cases, tandem processes were successful for constructing the rings.<sup>[8i]</sup> Although the reported methods are valuable for each purpose, they generally rely on reaction conditions involving strong bases and/or elevated temperatures, which makes them less likely to be applicable for the synthesis of various substituted pyrrole-based heterocycles. Due to these reasons, there are quite few methods that can be applied for the syntheses of indoles and all regio-isomeric azaindoles. To the best of our knowledge, only two synthetic methods, using Larock's heteroannulation<sup>[9]</sup> and Hegedus-Mori-Heck reaction, <sup>[10]</sup> can successfully make all regio-isomeric azaindoles. Therefore, it is necessary to develop more efficient, mild, and user-friendly methods with broad substrate tolerance to access diverse pyrrole-fused heterocycles for substituted indoles and all regio-isomeric azaindoles.

In the course of our drug discovery program, we became interested in developing an efficient method to prepare substituted indole-2-carboxylate derivatives. Of the syntheses based on metal-catalyzed cyclizations, reports related to the stepwise syntheses of substituted

indole-2-carboxylates attracted our attention, because of the potential for the current sequential approaches to be modified into cascade processes.<sup>[4c,8b,8f]</sup> In previous reports, a C=C bond was formed through the Horner-Wadsworth-Emmons olefination<sup>[11]</sup> of 2-bromo benzaldehydes with *N*-Cbz phosphonoglycine trimethyl ester, and the resulting enamines were cyclized to indoles using Pd- or Cu-catalyzed reactions. Although these results partially solved the issues related to the harsh conditions previously employed, these sequential strategies not only are time-consuming but also suffered from uncontrollable deprotection of the *N*-Cbz group.<sup>[8f]</sup> Thus, they were only applicable to a narrow scope of substrates as a result of the necessity of a strong base and/or a high reaction temperature.<sup>[8]</sup> Therefore, a mild, straightforward, versatile single-step reaction for the synthesis of diverse pyrrole-fused heterocycles is necessary.

### **Results and Discussion**

Among previously reported methods for a C=C double bond formation, we thought that the Horner-Wadsworth-Emmons olefination<sup>[11]</sup> using commercial reagents could be an optimal choice for the one-pot reaction for the synthesis of various aromatic ring-fused pyrroles including indoles and azaindoles, due to mild reaction conditions and exceptional selectivity to *Z*-alkenes, which is essential for the subsequent cyclization (Scheme 1).



**Scheme 1:** General Scheme of One-pot Horner-Wadsworth-Emmons Olefination and Intramolecular *N*-arylation Reactions.

We began our investigation with the coupling reaction of commercially available *N*-Cbz protected phosphonoglycine trimethylester with benzaldehydes possessing a boronic acid group at the 2-position for a subsequent metal-catalyzed intramolecular *N*-arylation. In general, Cu-catalyzed intermolecular *N*-arylations using arylboronic acids occurred under milder conditions than those using aryl-halides.<sup>[7a]</sup> However, an unusual cyclized compound was obtained when 2-formyl phenylboronic acid **1** was reacted with *N*-Cbz phosphonoglycine trimethyl ester (**Ha**) under Cu-catalyzed reaction conditions that were reported for the reaction of arylboronic acids with amines (Eq. 1).<sup>[12]</sup> With the 2-iodo substituted substrate, similar intramolecular *N*-arylations *via* known Cu- or Pd-catalyzed *N*-arylation conditions were not successful, according to a previous report by Taylor and Schriber.<sup>[8b]</sup>



Therefore, we began our research using 2-bromobenzaldehyde and Cbz-protected phosphonoglycine trimethyl ester (**Ha**). Pd(0)-catalyzed reaction gave a complex mixture of products (entry 1, Table 1). Cu(OAc)<sub>2</sub>-mediated conditions gave only the enamine intermediate **A** in good yield (entry 2. Table 1).<sup>[13]</sup> Additionally, Fukuyama's stoichiometric CuI/CsOAc mediated conditions<sup>[4c]</sup> and catalytic CuI/*L*-proline conditions<sup>[8f]</sup> did not result in cyclization of the enamine (entries 3-4, Table 1). Buchwald's diamine ligand-based conditions<sup>[14]</sup> (entries 5-7, Table 1) showed better results, but the yields still needed to be further improved. When the metal (0.4 eq.), 2,2'-bipyridine (bipy, 0.4 eq.), and K<sub>3</sub>PO<sub>4</sub> (6.0 eq.) were utilized in CH<sub>2</sub>Cl<sub>2</sub>, two substrates underwent smooth coupling to provide the

#### **Organic & Biomolecular Chemistry**

corresponding indole-2-carboxylates in decent yields at room temperature (entry 8, Table 1). The effects of a base and a solvent during the cyclization step were quite significant, and a large excess amount of  $K_3PO_4$  (6.0 eq.) in CH<sub>2</sub>Cl<sub>2</sub> afforded better results within shorter reaction time (entries 8, 9, and 11, Table 1). Unfortunately, lowering the amount of the catalyst below 0.4 eq. did not give full conversions, even after 24 h (entry 10, Table 1).

Table 1: Optimization of the One-pot Synthesis Using 2-Bromobenzaldehyde.

(1 mn	∕∼O + Br nol)	O, H O, H HN Cbz Ha (1.4 mmol)	Conditions	3	CO <sub>2</sub> Me N Cbz
ntrv	Co	onditions <sup>a</sup>	Ligand <sup>b</sup>		Indole 3

Entry	Conditions <sup>a</sup>	Ligand <sup>b</sup>	Indole 3 (A) $(\%)^{c}$
1	$Pd(PPh_3)_4$ (0.1 eq.), DMF, DIPEA(3.0 eq.) <sup>f</sup>	-	16 (-) <sup>c</sup>
2	Cu(OAc) <sub>2</sub> (2.0 eq.), Py. K <sub>2</sub> CO <sub>3</sub> (2.0 eq.)	-	- (79)
3	CuI (0.2 eq.), DMSO, CsOAc (3.0 eq.)	-	11 (62)
4	CuI (0.4 eq.), Tol. K <sub>3</sub> PO <sub>4</sub> (3.0 eq.)	<i>L</i> -Proline	9 (55)
5	CuI (0.4 eq.), Tol. K <sub>3</sub> PO <sub>4</sub> (3.0 eq.)		43 (29)
6	CuI (0.4 eq.), Tol. K <sub>3</sub> PO <sub>4</sub> (3.0 eq.)	<i>N</i> , <i>N</i> -Dimethyl ethylenediamine	34 (31)
$7^{\rm f}$	CuI (0.4 eq.), Tol. $K_3PO_4 (3.0 eq.)^g$		52 (-) <sup>d</sup>
8	CuI (0.4 eq.), CH <sub>2</sub> Cl <sub>2</sub> K <sub>3</sub> PO <sub>4</sub> (3.0 eq.)		68 (-)
9	CuI (0.4 eq.), CH <sub>2</sub> Cl <sub>2</sub> K <sub>3</sub> PO <sub>4</sub> (6.0 eq.)	2,2'-Bipyridyl	71 (-)
10	CuI (0.2 eq.), $CH_2Cl_2$ K <sub>3</sub> PO <sub>4</sub> (6.0 eq.)	(Bipy.)	45 (-) <sup>e</sup>
11	CuI (0.4 eq.), Tol. K <sub>3</sub> PO <sub>4</sub> (3.0 eq.)		29 (39)

<sup>&</sup>lt;sup>a</sup>Performed at rt for 12 h.; <sup>b</sup>40 mol% of a ligand was used.; <sup>c</sup>Large amount of inseparable complex mixture was obtained.; <sup>d</sup>15 % of Cbz-deperotected indole-2-carboxylate was obtained.; <sup>e</sup>22 % of the enamine A was still remained after 24 h.; <sup>f</sup>Reacted at 100 °C for 12 h.; Reacted at 100 °C for 2 h.

To understand the order of the one-pot reaction, we checked the reaction over time by <sup>1</sup>H NMR spectroscopy using the condition of entry 9 in Table 1 (Graph 1). The initial

formation of the enamine **A** occurred within an hour, and cyclization then occurred. Overall the one-pot reaction completed within 6 h even at room temperature, and prolonged reaction did not lower the yield of the reaction through deprotection of *N*-Cbz group, which has been a major concern in previous Cu- and Pd-catalyzed stepwise syntheses.



Graph 1: Profile of the One-pot Reaction.



Figure 3: Mild One-pot Reaction Products of Substituted Ortho-Bromobenzaldehydes.

Using the optimal conditions (entry 9, Table 1), substituted 2-bromobenzaldehydes were tested. Regardless of the electronic properties of the substituents (halogens (5-7) vs methoxy (4)), the reactions gave the desired compounds in good to excellent yields (Figure 3). However, most of the reactions needed longer reaction times (12 h) than unsubstituted 2bromobenzaldehyde for full conversions. Both commercially available Boc- and Cbzprotected phosphonoglycine trimethylesters (Ha-b) gave indole-2-carboxylates, and protection with the Boc group provided slightly better yields of the products in these substrates (10a vs 10b & 11a vs 11b). When 2-bromo-4-fluorobenzaldehyde and 2-bromo-4,6-difluorobenzaldehyde were utilized as starting materials, the reaction was slower, and a longer reaction time was required (24 h, 10a-b & 11a-b). Notably, these reaction conditions were specific for the bromine next to the carboxaldehyde (5 & 9). Previously, 7-formyl indole-2-carboxylates were prepared through 4-step syntheses based on Hemtsberger-Knittel's approach[15] in 14 % overall yields using azidoacetate.[16a] Additionally, Friedel-Crafts acylation of indole-2-carboxylate gave the 7-formyl compound as a mixture of regioisomers in a low yield.[16b] With our mild one-pot reaction using commercially available 2bromo-isophthaldehyde, the 7-formyl-substituted product **8** was efficiently prepared in excellent yields. Moreover, multiple substitutions at the 4 and 5 positions (**10a-b**), the 5 and 6 positions (**9**), and even 4, 5, and 6 positions (**11a-b**) were successfully synthesized. To further utilize the cyclized product **10a** for our medicinal project, 10 g-scale synthesis was performed. The desired product **10a** (9.2 g, 60 %) was obtained as an off-white solid, and most of the bipy ligand (2.4 g, 89 %) was recovered by acid-base work-up after the reaction.



Figure 4: Mild One-pot Reaction Products of heterocyclic substrates.

Next, we applied our method to *ortho*-bromopyridine carboxaldehyde derivatives for the synthesis of various azaindoles, which is one of the most promising templates for the development of various enzyme inhibitors including kinase inhibitors for treatment of various human diseases.<sup>[1,17]</sup> Previously, azaindole-2-carboxylate derivatives were primarily prepared using the Hemtsberger-Knittel synthesis, which is a stepwise synthesis and not amenable for 6- and 7-azaindoles.<sup>[18]</sup> Our exceptionally mild Cu-bipy conditions gave four types of azaindole-2-carboxylates in good to excellent yields without the loss of the *N*-Boc group, and additional halogen groups in the substrates remained intact (Figure 4). According to a

previous report, Cu/*L*-proline conditions gave only deprotected pyrrolo[2,3-*c*]pyridines.<sup>[87]</sup> Using the optimized Cu/bipy conditions, the 4-azaindole **12** was obtained from 3bromopyridine-2-carboxaldehyde in an excellent yield. For the 5-azaindole, 2-chloro substituted 4-bromopyridine-3-carboxylate was applied, and 5-azaindole **13** was obtained in lower yield. Substituted 6-azaindoles **14-16** were also prepared from their corresponding pyridines. Preparation of the 7-isomer **17** using 2-bromo pyridine-3-carboxaldehyde completed the series, demonstrating that *practically all 4- to 7-azaindoles with substitutions can be prepared using this method.* In addition, 3,4-Dibromo thiophene-2-carboxaldehyde and 2,5-dibromo thiophene-3-carboxaldehyde were smoothly converted into 4-bromo thieno[3,2-*b*]pyrrole compound **18** and 2-bromothieno- [2,3-*b*]pyrrole **19**, respectively. Moreover, tricyclic 1*H*-benzo[4,5]-thieno[3,2-*b*]pyrrole-2-carboxylate **20** was easily prepared by the same condition. Two of the crystalline products **16a** (CCDC 1031291) and **20** (CCDC 1031292) were unequivocally confirmed by X-ray crystallographic analysis (Figure 5).



Figure 5: X-ray Structures of 16a and 20.

### Conclusion

Overall, we have shown that various aromatic-ring fused pyrrole-2-carboxylates can be synthesized via one-pot Horner-Wadsworth-Emmons olefination and intramolecular *N*-arylation reactions under exceptionally mild conditions. Diverse *N*-protected indole-2-carboxylates containing mono to tri-substitutions at the 4- to 7- positions were easily prepared using commercially available reagents. Especially notable is that, these conditions were

applicable for the preparation of all regio-isomeric azaindole-2-carboxylate derivatives that could be useful templates for various medicinal projects. Additionally, thiophene- and benzothiophene-linked pyrroles were successfully obtained in good yields. Further applications of these compounds in our drug discovery programs will be reported in due course.

### **Experimental Section**

In an oven-dried flask, starting aldehyde (1.0 mmol), *N*-Cbz or *N*-Boc-2-phosphonoglycine trimethyl ester (1.4 mmol, 1.4 eq.), CuI (0.4 mmol, 40 mol%), 2,2'-bipyridine (0.4 mmol, 40 mol%) and  $K_3PO_4$  (6.0 mmol, 600 mol%) were dissolved in dry  $CH_2Cl_2$  (5 ml). The resulting mixture was stirred at rt for 6~24 h. After the reaction was completed, the mixture was filtered through a celite pad and evaporated. The residue was diluted with EtOAc (10 mL) then washed with 0.1 N HCl (5 mL) and brine (5 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. The crude product was purified by column chromatography and analyzed by LCMS and NMR.

#### Synthesis of borazaaromatic compound 2

*N*-Cbz-2-phosphonoglycine trimethyl ester (0.23 g, 0.70 mmol) and (2-formyl-4methoxyphenyl)boronic acid (90 mg, 0.50 mmol) were reacted using the same condition in the general procedure. Unexpected borazaaromatic compound **2** was obtained as colorless oil (0.105 g, 57 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.08-8.05 (d, *J* = 9.0 Hz, 1H, Ar), 7.66 (s, 1H, Ar), 7.38 (s, 5H, Ar), 7.05-7.02 (d, *J* = 9.0 Hz, 1H, Ar), 6.92-6.90 (d, *J* = 6.0 Hz, 2H, Ar), 5.26 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.87 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 3.55 (s, 3H, -O**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 165.28, 162.87, 156.93, 140.89, 134.88, 134.16, 130.08, 128.87, 128.80, 128.70, 118.74, 115.73, 111.40, 69.59, 55.28, 52.23; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>19</sub>H<sub>18</sub>BNO<sub>6</sub> 367.1227; found 367.1201.

#### Synthesis of 1-benzyl 2-methyl 1*H*-indole-1,2-dicarboxylate (3)

Colorless oil (0.109 g, 70 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.09-8.06 (d, J = 9.0 Hz, 1H, Ar), 7.59-7.56 (d, J = 9.0 Hz, 1H, Ar), 7.46-7.34 (m, 6H, Ar), 7.27-7.22 (t, J = 7.5 Hz, 1H, Ar), 7.11 (s, 1H, Ar), 5.40 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.71 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 162.21, 150.72, 137.66, 134.52, 130.37, 128.83, 128.78, 128.72, 127.67, 127.12, 123.69, 122.29, 115.69, 115.07, 69.69, 52.33; LCMS (ESI) 310.2 (M+H<sup>+</sup>; calc' for C<sub>18</sub>H<sub>16</sub>NO<sub>4</sub> 310.1).

#### Synthesis of 1-benzyl 2-methyl 5-methoxy-1*H*-indole-1,2-dicarboxylate (4)

Colorless oil (0.167 g, 98 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.98-7.95 (d, J = 9.0 Hz, 1H, Ar), 7.47-7.36 (m, 5H, Ar), 7.04-7.01 (m, 3H, Ar), 5.40 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.84 (s, 1H, -CO<sub>2</sub>**CH**<sub>3</sub>), 3.72 (s, 1H, -O**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 162.21, 156.48, 150.66, 134.53, 132.37, 130.84, 128.80, 128.74, 128.70, 128.41, 116.52, 115.98, 115.42, 103.90, 69.58, 55.67, 52.30; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>19</sub>H<sub>17</sub>NO<sub>5</sub> 339.1107; found 339.1105.

#### Synthesis of 1-benzyl 2-methyl 5-bromo-1*H*-indole-1,2-dicarboxylate (5)

White solid (0.175 g, 90 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.98-7.95 (d, J = 9.0 Hz, 1H, Ar), 7.74 (s, 1H, Ar), 7.51-7.48 (d, J = 9.0 Hz, 1H, Ar), 7.45-7.39 (m, 5H, Ar), 7.04 (s, 1H, Ar), 5.41 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.72 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 159.23, 147.73, 133.58, 131.62, 128.80, 127.33, 126.72, 126.37, 126.24, 126.17, 122.14, 114.33, 114.00, 111.55, 67.37, 49.86; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>18</sub>H<sub>14</sub>BrNO<sub>4</sub> 387.0106; found 387.0106. White solid (0.124, 80%); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.04-8.01 (d, J = 9.0 Hz, 1H, Ar), 7.56 (s, 1H, Ar), 7.37-7.34 (d, J = 9.0 Hz, 1H, Ar), 7.00 (s, 1H, Ar), 3.92 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 1.62 (s, 9H, -C(**CH**<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.99, 148.85, 136.00, 131.55, 128.91, 128.56, 126.97, 121.47, 116.05, 113.49, 85.09, 52.44, 27.77.; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>15</sub>H<sub>16</sub>ClNO<sub>4</sub> 309.0768; found 309.0764.

#### Synthesis of 1-tert-butyl 2-methyl 6-fluoro-1H-indole-1,2-dicarboxylate (7)

White solid (0.145 g, 98 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.83-7.79 (d, J = 12.0 Hz, 1H, Ar), 7.55-7.50 (dd, J = 6.0 Hz, 1H, Ar), 7.07 (s, 1H, Ar), 7.05-6.98 (dt, J = 3.0 Hz, 1H, Ar), 3.91 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 1.62 (s, 9H, -C(**CH**<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 163.94, 161.94, 160.71, 148.97, 138.38, 138.21, 130.81, 123.74, 123.18, 123.04, 114.68, 112.25, 111.92, 102.30, 101.92, 85.03, 52.31, 27.77; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>15</sub>H<sub>16</sub>FNO<sub>4</sub> 293.1063; found 293.1057.

#### Synthesis of 1-tert-butyl 2-methyl 7-formyl-1H-indole-1,2-dicarboxylate (8)

Yellow oil (0.130 g, 85 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 10.42 (s, 1H, CHO), 7.88-7.83 (t, J = 7.5 Hz, 2H, Ar), 7.42-7.37 (t, J = 7.5 Hz, 1H, Ar), 7.25 (s, 1H, Ar), 3.94 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.62 (s, 9H, -C(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 189.71, 161.56, 149.78, 135.29, 131.83, 129.38, 128.98, 127.84, 124.91, 123.12, 114.50, 86.23, 52.39, 27.62; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>16</sub>H<sub>17</sub>NO<sub>5</sub> 303.1107; found 303.1075.

#### Synthesis of 1-benzyl 2-methyl 6-bromo-5-methoxy-1*H*-indole-1,2-dicarboxylate (9)

White solid (0.145 g, 69 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ : 8.34 (s, 1H, Ar), 7.47-7.39 (m, 5H, Ar), 7.03 (s, 1H, Ar), 7.02 (s, 1H, Ar), 5.41 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.93 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 3.72 (s, 3H, -**OCH**<sub>3</sub>); <sup>13</sup>C NMR δ (CDCl<sub>3</sub>) : 161.93, 152.78, 150,32, 134.30, 132.25, 130.94,

128.93, 128.82, 128.76, 127.49, 119.91, 115.00, 112.48, 103.28, 69.87, 56.54, 52.41; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>19</sub>H<sub>16</sub>NO<sub>5</sub> 417.0212; found : 417.0223.

#### Synthesis of 1-benzyl 2-methyl 4-fluoro-5-methoxy-1*H*-indole-1,2-dicarboxylate (10a)

Off-white solid (0.124 g, 69 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.79-7.76 (d, *J* = 9.0 Hz, 1H, Ar), 7.46-4.39 (m, 5H, Ar), 7.16 (s, 1H, Ar), 7.13-7.08 (t, *J* = 7.5 Hz, 1H, Ar), 5.40 (s, 2H, - **CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.93 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 3.72 (s, 3H, -O**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.77, 150.54, 146.35, 144.36, 142.87, 142.80, 134.30, 133.23, 133.18, 131.22, 128.91, 128.80, 128.74, 118.84, 118.18, 115.44, 110.61, 69.83, 57.87, 52.47; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>19</sub>H<sub>16</sub>FNO<sub>5</sub> 357.1013; found : 357.1022.

Synthesis of 1-*tert*-butyl 2-methyl 4-fluoro-5-methoxy-1*H*-indole-1,2-dicarboxylate (10b) White solid (0.138 g, 85 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.80-7.77 (d, *J* = 9.0 Hz, 1H, Ar), 7.15-7.09 (m, 2H, Ar), 3.94 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 3.92 (s, 3H, -OCH<sub>3</sub>), 1.61 (s, 9H, -C(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.89, 149.07, 147.00, 143.69, 142.55, 142.44, 133.63, 133.53, 131.27, 118.20, 117.95, 115.37, 110.46, 110.40, 109.76, 84.90, 57.93, 52.44, 27.78; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>16</sub>H<sub>18</sub>FNO<sub>5</sub> 323.1169; found : 323.1161.

## Synthesis of 1-benzyl 2-methyl 4,6-difluoro-5-methoxy-1*H*-indole-1,2-dicarboxylate (11a)

White solid (0.158 g, 84 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ : 7.69-7.65 (d, J = 12.0 Hz, 1H, Ar), 7.47-7.37(m, 5H, Ar), 7.16 (s, 1H, Ar), 5.40 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 4.00 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 3.72 (s, 3H, -O**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.34, 157.75, 150.24, 134.05, 130.67, 130.61, 129.03, 128.88, 128.77, 113.78, 110.84, 110.82, 99.46, 99.40, 99.10, 99.04, 70.12, 62.39, 52.47; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>19</sub>H<sub>15</sub>F<sub>2</sub>NO<sub>5</sub> 375.0918; found : 375.0891.

## Synthesis of 1-tert-butyl 2-methyl 4,6-difluoro-5-methoxy-1H-indole-1,2-dicarboxylate (11b)

Colorless oil (0.149 g, 87 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.70-7.66 (d, J = 12.0 Hz, 1H, Ar), 7.13 (s, 1H, Ar), 4.00 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 3.92 (s, 3H, -OCH<sub>3</sub>), 1.62 (s, 9H, -C(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR δ (CDCl<sub>3</sub>) : 161.48, 157.70, 157.63, 154.42, 154.36, 150.29, 150.19, 148.74, 146.95, 146.86, 132.74, 130.71, 130.66, 113.85, 113.83, 113.58, 113.56, 110.04, 110.01, 99.18, 99.12, 98.82, 98.76, 85.48, 62.39, 52.46, 27.72; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>16</sub>H<sub>17</sub>F<sub>2</sub>NO<sub>5</sub> 341.1075; found : 341.1067.

#### Synthesis of 1-*tert*-butyl 2-methyl 1*H*-pyrrolo[3,2-*b*]pyridine-1,2-dicarboxylate (12)

Colorless oil (0.130 g, 94 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.61-8.59 (d, J = 6.0 Hz, 1H, Ar), 8.38-8.35 (d, J = 9.0 Hz, 1H, Ar), 7.34-7.30 (dd, J = 7.5 Hz, 1H, Ar), 7.22 (s, 1H, Ar), 3.96 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.63 (s, 9H, -C(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR δ (CDCl<sub>3</sub>) : 162.04, 148.43, 146.63, 145.63, 133.21, 131.22, 122.63, 120.84, 114.26, 85.55, 52.64, 27.76; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> 276.1114; found : 276.1114.

## Synthesis of 1-tert-butyl 2-methyl 4-chloro-1H-pyrrolo[3,2-c]pyridine-1,2-dicarboxylate (13)

Colorless oil (0.074 g, 47 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.31-8.29 (d, J = 6.0 Hz, 1H, Ar), 7.90-7.88 (d, J = 6.0 Hz, 1H, Ar), 7.20 (s, 1H, Ar), 3.96 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.64 (s, 9H, - $C(CH_3)_3$ ; <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.26, 147.94, 145.41, 145.07, 142.83, 131.48, 122.82, 111.93, 109.26, 86.43, 52.73, 27.70; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C14H15CIN2O4 310.0720; found 310.0711.

Synthesis of 1-tert-butyl 2-methyl 1H-pyrrolo[2,3-c]pyridine-1,2-dicarboxylate (14)

Colorless oil (0.089 g, 64 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 9.42 (s, 1H, Ar), 8.47 (s, 1H, Ar), 7.54-7.52 (d, J = 6.0 Hz, 1H, Ar), 7.00 (s, 1H, Ar), 3.96 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.66 (s, 9H, -C(CH<sub>3</sub>) <sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 162.10, 148.23, 142.43, 137.96, 135.88, 133.38, 133.06, 111.75, 85.94, 52.80, 27.87; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> 276.1110; found 276.1099.

## Synthesis of 1-*tert*-butyl 2-methyl 4-bromo-1*H*-pyrrolo[2,3-*c*]pyridine-1,2-dicarboxylate (15)

White solid (0.091 g, 51 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 9.32 (s, 1H, Ar), 8.54 (s, 1H, Ar), 7.06 (s, 1H, Ar), 3.97 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.66 (s, 9H, -C(CH<sub>3</sub>) <sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.59, 147.85, 143.25, 136.42, 133.85, 133.73, 133.49, 113.05, 111.31, 86.55, 52.91, 27.80; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>14</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>4</sub> 354.0215; found 354.0219.

## Synthesis of 1-benzyl 2-methyl 5-chloro-1*H*-pyrrolo[2,3-*c*]pyridine-1,2-dicarboxylate (16a)

White solid (0.154 g, 89 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 9.12 (s, 1H, Ar), 7.53 (s, 1H, Ar), 7.48-7.39 (m, 5H, Ar), 6.94 (s, 1H, Ar), 5.45 (s, 2H, -**CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.77 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.46, 149.35, 144.36, 137.31, 136.39, 135.00, 133.61, 132.43, 129.29, 129.05, 128.93, 128.91, 115.92, 111.24, 70.65, 52.93; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>17</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>4</sub> 344.0564; found 344.0558.

## Synthesis of 1-*tert*-butyl 2-methyl 5-chloro-1*H*-pyrrolo[2,3-*c*]pyridine-1,2-dicarboxylate (16b)

Yellow oil (0.147 g, 94 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ : 9.17 (s, 1H, Ar), 7.54 (s, 1H, Ar), 6.92 (s, 1H, Ar), 3.97 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.65 (s, 9H, -C(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR δ (CDCl<sub>3</sub>) :

161.64, 147.83, 143.88, 137.21, 136.15, 135.05, 132.62, 115.76, 110.50, 86,41, 52.92, 27.80; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>14</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>4</sub> 310.0720; found 310.0701.

#### Synthesis of 1-*tert*-butyl 2-methyl 1*H*-pyrrolo[2,3-*b*]pyridine-1,2-dicarboxylate (17)

White solid (0.111 g, 80 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.60-8.59 (d, J = 3.0 Hz, 1H, Ar), 7.98-7.95 (d, J = 9.0 Hz, 1H, Ar), 7.23-7.21(m, 1H, Ar), 7.09 (s, 1H, Ar), 3.94 (s, 3H, -CO<sub>2</sub>CH<sub>3</sub>), 1.64 (s, 9H, -C(CH<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.59, 149.48, 147.93, 147.71, 130.79, 129.82, 119.77, 119.01, 111.21, 85.22, 52.44, 27.69; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub> 276.1110; found 276.1089.

## Synthesis of 4-*tert*-butyl 5-methyl 3-bromo-4*H*-thieno[3,2-*b*]pyrrole-4,5-dicarboxylate (18)

white solid (0.166 g, 92 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ : 7.30 (s, 1H, Ar), 7.11 (s, 1H, Ar), 3.88 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 1.67 (s, 9H, -C(**CH**<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR δ (CDCl<sub>3</sub>) : 160.62, 148.00, 137.72, 128.51, 127.61, 124.68, 110.59, 94.92, 86.23, 52.04, 27.51; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>13</sub>H<sub>14</sub>BrNO<sub>4</sub>S 358.9827; found 358.9799.

## Synthesis of 6-*tert*-butyl 5-methyl 2-bromo-3a*H*-thieno[2,3-*b*]pyrrole-5,6(6a*H*)dicarboxylate (19)

Colorless oil (0.45 g, 80 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 7.03 (s, 1H, Ar), 7.02 (s, 1H, Ar), 3.88 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>), 1.64 (s, 9H, -C(**CH**<sub>3</sub>)<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 160.78, 147.41, 139.11, 128.85, 128.05, 120.49, 114.29, 110.00, 86.14, 52.17, 27.86.; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>13</sub>H<sub>14</sub>BrNO<sub>4</sub>S 358.9827; found 358.9844.

Synthesis of 1-benzyl 2-methyl 1H-benzo[4,5]thieno[3,2-b]pyrrole-1,2(3aH,8bH)dicarboxylate (20) Yellow crystal (0.158 g, 86 %); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  : 8.46-8.43 (t, *J* = 4.5 Hz, 1H, Ar), 7.80-7.77 (t, *J* = 4.5 Hz, 1H, Ar), 7.48-7.34 (m, 7H, Ar), 7.19 (s, 1H, Ar), 5.47 (s, 2H, - **CH**<sub>2</sub>(C<sub>6</sub>H<sub>5</sub>)), 3.73 (s, 3H, -CO<sub>2</sub>**CH**<sub>3</sub>); <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>) : 161.00, 150.89, 144.10, 136.25, 134.05, 129.53, 129.02, 128.98, 128.72, 126.52, 125.21, 124.66, 123.80, 123.03, 113.90, 70.68, 52.14.; HRMS (EI) m/z: [M<sup>+</sup>] Calcd' for C<sub>20</sub>H<sub>15</sub>NO<sub>4</sub>S 365.0722; found 365.0676.

### **Supporting Information**

Copies of <sup>1</sup>H and <sup>13</sup>C NMR Data are available on the web.

### Acknowledgements

Financial support provided by the KRICT(SI-1404) and Ministry of Knowledge Economy, Republic of Korea is gratefully acknowledged.

## References

[1] a) J. A. Joule, K. Mills, Heterocyclic Chemistry, 5th Ed. 2010, Wiley-Blackwell; b) T.
 Eicher, S. Hauptmann, A. Speicher, The Chemistry of Heterocycles: Structures, Reactions,
 Synthesis, and Application 3rd Ed. 2012, Wiley.

[2] a) L. Knorr, Ber. 1884, 17, 2863; Paal, C. *Ber.* 1884, *17*, 2756; b) A. Hantzsch, *Ber.*1881, *14*, 1637; c) W. G. Terry, A. H. Jackson, G. W. Kenner, G. Kornis, *J. Chem. Soc.*, 1965, 4389; d) For a recent review, see V. Estévez, M. Villacampa, C. Menéndez, *Chem. Soc. Rev.*2010, *39*, 4402 and references cited therein.

[3] For recent reviews of the synthesis of indole, see a) R. J. Sundberg, Indoles. AcademicPress Ltd. San Diego: 1996; b) D. F. Taber, P. K. Tirunahari, *Tetrahedron*, 2011, 67, 7195.

[4] a) B. Frydman, S. Reil, M. E. Despuy, H. Rapoport, J. Am. Chem. Soc. 1969, 91,
2338; b) P. Carter, S. Fitzjohn, S. Halazy, P. Magnus, J. Am. Chem. Soc. 1987, 109, 2711; c)
K. Yamada, T. Kurokawa, H. Tokuyama, T. Fukuyama, J. Am. Chem. Soc. 2003, 125, 6630.

[5] a) Nicotinamide phosphoribosyltransferase inhibitor, see G. R. W. Pitt, P. A. Mayes, L. Andrau, WO 2013020164, 2013; b) Myt1 inhibitor, see M. A. Lago, WO 2000033842, 2000; *Chem. Abstr.* 2001, *135*, 211033; c) CHK1 inhibitor, see J. -G. Parmentier, B. Portevin, R. M. Golsteyn, A. Pierré, J. Hickman, P. Gloanec, G. D. Nanteuil, *Bioorg. Med. Chem. Lett.* 2009, *19*, 841; d) Human histamine H4 receptor, see H. Cai, N. I. Carruthers, C. A. Dvorak, J. P. Edward, A. K. Kwok, US 20040048878, 2004; e) Respiratory syncycial virus, see G. R. W. Pitt, P. A. Mayes, L. Andrau, WO 2013020164, 2013.

[6] For an example of pyrrole containing materials for chemosensors, see a) M. Lazerges,
K. I. Chane-Ching, S. Aeiyach, S. Chelli, B. Peppin-Donnat, M. Billon, C. Lombard, F. Maurel, M. Jouini, *J. Solid State Electrochem.*, 2009, *13*, 231; b) For glucose sensors, see A. Kros, S. W. F. M. van Hövel, R. J. M. Nolte, N. A. J. M. Sommerdijk, *Sens. Actuators, B*, 2001, *80*, 229; c) For detectors of volatile organic compounds, see S. Hamilton, M. J. Hepher,
J. Sommerville, *Sens. Actuators, B*, 2005, *107*, 424; d) For a review of pyrrole-containing dye, see: A. Loudet, K. Burgess, *Chem. Rev.*, 2007, *107*, 4891.

[7] For reviews of metal-catalyzed N-arylations involving copper, see a) S. V. Ley, A. W.
Thomas, Angew. Chem., Int. Ed. 2003, 42, 5400; b) F. Monnier, M. Taillefer, Angew. Chem.,
Int. Ed. 2009, 48, 6954; c) T. Liu, H. Fu, Synthesis 2012, 44, 2805; for reviews involving
palladium, see d) J. F. Hartwig, Acc. Chem. Res. 2008, 41, 1534; e) D. S. Surry, S. L.
Buchwald, Chem. Sci. 2011, 2, 27; f) C. Fischer, B. Koenig, Beilstein J. Org. Chem. 2011, 7,
59; g) J. E. R. Sadig, M. C. Willis, Synthesis 2011, 43, 1.

[8] For indoles via Pd-catalyzed intramolecular N-arylations, see a) K. Aoki, A. J. Peat, S.
L. Buchwald, J. Am. Chem. Soc. 1998, 120, 3068; b) J. A. Brown, Tetrahedron Lett. 2000, 41, 1623; c) K. Yamazaki, Y. Nakamura, Y. Kondo, J. Chem. Soc., Perkin Trans. 1 2002, 2137;

d) K. Yamazaki, Y. Nakamura, Y. Kondo, J. Org. Chem. 2003, 68, 6011; e) J. Barluenga, A. Jiménez-Aquino, C. Valdés, F. Aznar, Angew. Chem., Int. Ed. 2007, 46, 1529; using Cucatalyzed conditions, see f) C. Barberis, T. D. Gordon, C. Thomas, X. Zhang, K. P. Cusack, Tetrahedron Lett. 2005, 46, 8877; g) F. S. Melkonyan, A. V. Karchava, M. A. Yurovskaya, J. Org. Chem. 2008, 73, 4275; h) A. M. Taylor, S. L. Schreiber, Tetrahedron Lett. 2009, 50, 3230; i) Q. Cai, Z. Li, J. Wei, C. Ha, D. Pei, K. Ding, Chem. Commun. 2009, 7581; j) R. Besandre, M. Jaimes, J. A. May, Org. Lett. 2013, 15, 1666.

[9] a) R. C. Larock, E. K. Yum, J. Am. Chem. Soc. 1991, 113, 6689; b) X. Li, W. Yin, P.
V. V. Sarma, H. Zhou, J. Ma, J. M. Cook, Tetrahedron Lett. 2004, 45, 8569.

[10] a) N. Lachance, M. April, *Synthesis*, **2005**, 2571; b) M. Nazaré, C. Schneider, A. Lindenschmidth, D. W. Will, *Angew. Chem. Int. Ed.* **2004**, *43*, 4526.

[11] For reviews, see a) B. E. Maryanoff, A. B. Reitz, *Chem. Rev.* 1989, *89*, 863; b) M.
Edmonds, A. Abell, In Modern Carbonyl Olefination Methods and Applications; T. Takeda,
Ed.; Wiley-VCH: Weinheim, Germany, 2004, pp. 1-17; c) B. J. Walker, In Organophosphorus
Reagents in Organic Synthesis; J. I. G. Gadogan, Ed.; Academic Press: London, UK, 1979, pp.
155-205; for an relevant example of heterocycle syntheses using HWE reaction, see d) C. W.
Muir, A. R. Kennedy, J. A. Redmond, A. J. B. Watson, *Org. Biomol. Chem.* 2013, *11*, 3337.

[12] Similar borazaaromatic compounds were reported previously, see P. R. Ashton, K. D.
M. Harris, B. M. Kariuki, D. Philp, J. M. A. Robinson, N. Spencer, *J. Chem. Soc., Perkin Trans.* 2, 2001, 2166.

[13] a) P. Y. S. Lam, C. G. Clark, S. Saubern, J. Adams, M. P. Winters, D. M. T. Chan, A. Combs, *Tetrahedron Lett.* 1998, *39*, 2941; b) A. P. Combs, S. Saubern, M. Rafalski, P. Y. S. Lam, *Tetrahedron Lett.* 1999, *40*, 1623; c) P. Y. S. Lam, C. G. Clark, S. Saubern, J. Adams, K. M. Averill, D. M. T. Chan, A. Combs, *Synlett* 2000, 674.

[14] J. C. Antilla, A. Klapars, S. L. Buchwald, J. Am. Chem. Soc. 2002, 124, 11684.

[15] H. Hemtsberger,; D. Knittel, H. Wiedmann, Monatsh. Chem. 1970, 101, 161.

[16] Former syntheses of 7-formyl indole-2-carboxylate, see a) D. L. Boger, WO 2004101767, 2004; b) M. Tani, T. Aoki, S. Ito, S. Matsumoto, M. Hideshima, K. Fukushima, R. Nozawa, T. Maeda, M. Tashiro, Y. Yokoyama, Y. Murakami, *Chem. Pharm. Bull.* 1990, 38, 3261.

[17] For general reviews of azaindole synthesis, see a) F. Popowycz, S. Routier, B. Joseph,
J. -Y. Mérour, *Tetrahedron* 2007, 63, 1031; b) F. Popowycz, J.-Y. Mérour, B. Joseph, *Tetrahedron* 2007, 63, 8689; c) J. J. Song, J. T. Reeves, F. Gallou, Z. Tan, N. K. Yee, C. H.
Senanayake, *Chem. Soc. Rev.* 2007, 36, 1120 and references cited therein.

[18] a) P. M. Fresneda, P. Molina, S. Delgado, J. A. Bleda, *Tetrahedron Lett.* 2000, 41, 4777; b) T. Lomberget, S. Radix, R. Barret, *Synlett* 2005, 2080; c) P. Roy, M. Boisvert, Y. Leblanc, *Org. Synth.* 2007, 84, 262.